SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Daiichi Sankyo, Inc. Completes Enrollment in Hokusai - VTE, Investigating Once-Daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE